Improvement in Obesity-Related Comorbidities 5 Years After Endoscopic Sleeve Gastroplasty: A Prospective Cohort Study.

Background And Aims: Endoscopic sleeve gastroplasty (ESG) is a minimally invasive bariatric procedure that the gastric cavity to facilitate weight loss. We aimed to evaluate the long-term effects of ESG as a monotherapy on obesity-related comorbidities over five years.

Methods: This prospective study analyzed data from 404 consecutive patients (45±11.

Using Second-Generation Anti-Obesity Medications.

Second-generation anti-obesity medications are more effective than their first-generation predecessors, resulting in an average weight loss of 15% when combined with lifestyle modifications. This article examines the efficacy and therapeutic implications of the three currently approved second-generation medications: setmelanotide for individuals with monogenic forms of obesity, semaglutide 2.4 mg, and tirzepatide.

Tirzepatide for Obesity Treatment and Diabetes Prevention.

Background: Obesity is chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes.